Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative option for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
• Despite advances, relapse and refractory disease persist post-transplant, necessitating improved strategies.
• Optimizing patient counseling, donor selection, and transplant type is crucial for maximizing allo-HCT benefits.

Purpose of the Study:

• To explore novel maintenance strategies after allo-HCT to improve patient outcomes.
• To investigate targeted immunotherapies for controlling persisting or relapsed hematologic malignancies.
• To enhance the balance between graft-versus-host disease (GVHD), relapse, and infection post-transplant.

Main Methods:

• Utilizing purified blood stem cell grafts combined with ex vivo expanded T-cells from donors.
• Generating T-cells targeting infectious agents and common leukemic antigens (e.g., WT1, PRAME, survivin, NY-ESO).
• Employing partially HLA-matched third-party T-cells from cryopreserved banks for generating antigen-specific T-cells.

Main Results:

• Donor-derived CMV- and EBV-specific T-cells have demonstrated clinical value in preventing infections.
• Trials are underway using donor-derived cytotoxic T-cells targeting multiple leukemic antigens.
• Donor-derived CAR19 T-cells are being investigated as a post-allo-HCT therapy for acute leukemia.

Conclusions:

• Targeted immunotherapies, including donor-derived T-cells, show promise for improving allo-HCT outcomes in AML and MDS.
• Further research into selective immunomodulation and T-cell-based therapies is essential for reducing relapse and infection.
• Optimizing T-cell strategies can help mitigate GVHD while enhancing anti-leukemic effects.